Home › Oligomerix Awarded A Grant For Its Alzheimer's Drug Discovery Program Targeting Tau Oligomers From The National Institutes Of Health
 

Keywords :   


Oligomerix Awarded A Grant For Its Alzheimer's Drug Discovery Program Targeting Tau Oligomers From The National Institutes Of Health

2016-05-03 02:45:01| drugdiscoveryonline News Articles

Oligomerix, Inc., a privately held company targeting tau oligomers for developing disease modifying therapeutics for Alzheimer’s disease (AD) and related neurodegenerative disorders, announced recently the receipt of an award for a Direct-to-Phase-II Small Business Innovation Research (SBIR) grant for a two year program for a total of $1.5 M from the National Institutes of Health (NIH), National Institute on Aging (NIA)

Tags: of health program national

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
05.11Shoppers warned over luxury advent calendar scams
05.11Durable Floor Coating from HMG Paints Transforms FC United\'s SMRE Bar
05.11Teknos Poland Honored by Farby i Lakiery
05.11Xumo teams up with Target to offer Hisense Xumo TVs
05.11KT launches 8K AI-powered IPTV set-top box
05.11Tropical Storm Rafael Graphics
More »